Bisphosphonate use has expanded beyond traditional applications, such as the prevention of osteoporosis, into non-traditional pediatric low bone mass diseases including osteogenesis imperfecta (OI) . Despite enthusiasm, some questions remain on the overall effectiveness and implications of long-term treatment. In the Brtl/+ mouse model for OI, bisphosphonate treatment improves bone size, but bending strength fails to increase to proportionate levels and bones remain brittle . Complications associated with long-term bisphosphonate treatment have been noted in other systems [3,4] leading to a need for critical information describing local drug-cell interactions responsible for these observations. The purpose of this study was to validate a fluorescent bisphosphonate analog, far-red fluorescent pamidronate (FRFP)  as a biomarker of bisphosphonate deposition and retention in vivo to monitor local drug concentration in a site-specific manner.
- Bioengineering Division
Near-Infrared Imaging Reveals Site- and Age-Specific Localization of Bisphosphonate Delivery and Retention in Model of Osteogenesis Imperfecta
- Views Icon Views
- Share Icon Share
- Search Site
Kozloff, KM, Volakis, LI, Marini, JC, & Caird, MS. "Near-Infrared Imaging Reveals Site- and Age-Specific Localization of Bisphosphonate Delivery and Retention in Model of Osteogenesis Imperfecta." Proceedings of the ASME 2009 Summer Bioengineering Conference. ASME 2009 Summer Bioengineering Conference, Parts A and B. Lake Tahoe, California, USA. June 17–21, 2009. pp. 49-50. ASME. https://doi.org/10.1115/SBC2009-205344
Download citation file: